Protagonist Therapeutics, Inc — Director's Dealing 2021

Jan 21, 2021

SEC Form 4 — Statement of Changes in Beneficial Ownership

Issuer: Protagonist Therapeutics, Inc (PTGX)
CIK: 0001377121
Period of Report: 2021-01-19

Reporting Person: PATEL DINESH V PH D (Director, President and CEO)

Non-Derivative Transactions

Date	Security	Code	Shares	Price	A/D	Holdings After	Ownership
2021-01-19	Common Stock	M	13000	$4.21	Acquired	450990	Direct
2021-01-19	Common Stock	S	24846	$24.5957	Disposed	426144	Direct

Derivative Transactions

Date	Security	Exercise Price	Code	Shares	A/D	Expiration	Underlying	Ownership
2021-01-19	Stock Option (right to buy)	$4.21	M	13000	Disposed	2026-04-29	Common Stock (13000)	Direct

Footnotes

F1: The sales reported in this Form 4 include: (a) the open market sale of 13,000 shares of common stock acquired pursuant to the exercise of options to purchase common stock; and (b) the open market sale of an additional 11,846 shares of common stock. Such transactions were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on November 6, 2020.

F2: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $24.01 to $24.95, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range.

F3: 1/48th of the shares subject to the option vested on the last day of each month following the vesting commencement date. The option became fully vested on April 25, 2020.